Eighteen children from 3 weeks to 6.9 years of age were given an oral acyclovir suspension for herpes simplex or varicella-zoster virus infections. Thirteen patients who were 6 months to 6.9 years old received 600 mg/M2 per dose, and three infants and two children less than 2 years old were given 300 mg/M2 per dose. The drug was given four times a day, except to one infant who was treated with three doses a day. Among the 13 children who received the 600-mg/M2 dose, the maximum concentration in plasma (Cmax) was 0.99 0.38 p,g/ml (mean + standard deviation), the time to maximum concentration (Tmax) was 3.0 0.86 h, the area under the curve (AUC) was 5.56 2.17 p,g h/ml, and the elimination half-life (tl/2) was 2.59 0.78 h. The three infants less than 2 months of age who received the 300-mg/M2 dose had a Cmax of 1.88 ± 1.11 ,g/ml, a Tmax of 4.10 ± 0.48 h, an AUC of 6.54 ± 4.32 ,ugg h/ml, and a tl/2 of 3.26 ± 0.33 h. The acyclovir suspension was well tolerated by young children. No adverse effects requiring discontinuation of the drug occurred.
Acyclovir [9-(2-hydroxyethoxymethyl)guanine] is a nucleoside analog which inhibits the replication of herpes simplex virus (HSV) and varicella-zoster virus (VZV). Acyclovir administered parenterally is effective for the treatment of neonatal HSV infections, HSV encephalitis, and genital HSV infections (3, 25, 26) . In immunosuppressed patients, intravenous acyclovir is useful for the therapy and suppression of HSV infections and for the therapy of VZV infections (6, 9, 10, 14, (18) (19) (20) . The oral administration of acyclovir is of benefit for the therapy and suppression of genital HSV infections in the normal adult host (2, 5, 9, 11, 17, 23) and for the treatment and suppression of recurrent mucocutaneous HSV infections in immunocompromised patients (14, 22) .
Pharmacokinetic information is available for acyclovir administered intravenously to adults and children and for the capsule formulation given to adults (4, 18) . The pharmacology of oral acyclovir tablets has been investigated in children (12, 13) . A liquid suspension formulation of the drug was developed for children and other patients who cannot ingest medications in solid form. The purpose of our study was to determine the pharmacokinetics and tolerance of acyclovir suspension in children.
(This work was presented in part at the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, La., 28 (height of patient/crea,tinine concentration in serum) (21, 24 Fig. 1 . Among patients'receiving 300 m,g/im2, the three infants less than 2 months of age had higher mean concentrations 2 to 8 h after the last dose than did the two children who were 1.5 and 1.8 years of age (Table 2) .
Pharmacokinetic analysis. Pharmacokinetic parameters determined from individual patient data after the last dose are than did the older children receiving the same or a higher dose (Table 3) .
By using interpolation and superimposition of mean data, the steady-state acyclovir concentrations in plasma were simulated for the 600-mg/M2 dose (Fig. 2) . The expected peak acyclovir concentrations after four consecutive doses given at 4-h intervals were approximately 0.9, 1.3, 1.4, and 1.5 p.g/ml after successive doses during the day.
Adverse reactions. Three patients experienced adverse clinical reactions which were self-limited and did not require discontinuation of the drug. The adverse effects were mild diarrhea, mild vomiting, or profuse diaphoresis.
Minor variations were observed in the hepatic transaminase levels in seven patients, but five patients had elevated transaminase levels before acyclovir was begun. None of the patients had SGOT or SGPT greater than twice the normal value. Preexisting hematologic abnormalities in patients with malignancy and nephrotic syndrome persisted during the study, as did anemia in the infant with eczema. The older patient with eczema had a decline in hemoglobin from 12 per m2 per dose had mean values for Cmax of 0.99 ,ug/ml and t1/2 of 2.59 h. On the basis of body surface area, these children received the equivalent of five times the adult oral dose of 200 mg, but the peak concentration in plasma was only twofold higher than the peak concentration in plasma in adults. Thus, with identical dosage regimens, the peak concentration in plasma in children would be about 40% of the expected peak level in adults. This difference can be explained in part by the fact that the Cmax in the present study was determined after a dose given 12 h after the previous dose. In the adult pharmacokinetic study, the Cmax was measured at steady state in subjects receiving the drug every 4 h in each 24-h period. The lower peak concentrations in children probably also reflect slower absorption of the drug from the suspension compared with the rate of absorption fron capsules given to adults. In contrast to the difference in Cmax, the dose-normalized AUC in children given acyclovir suspension was approximately 75% of that after capsule administration to adults.
The mean Cmax after a 300-mg/m2 dose and the AUC were proportionately less than the values for 600 mg/m2. Only three infants less than 2 months of age received oral acyclovir suspension. However, the administration of the 300-mg/M2 dose produced a higher Cmax and a longer t112. The estimated CLCR in these patients was 50 ml/min per 1.73 m2, which reflects immature renal function in this age group and probably accounts for the higher concentrations of acyclovir in plasma. As was expected, the concentrations of acyclovir in plasma after its oral administration to children were significantly lower than those observed with intravenous therapy. Children given doses of 250 mg of acyclovir per m2 intravenously had a mean Cmax of 10.3 ± 4.0 jig/ml. Doubling the dose to 500 mg/M2 produced a mean Cmax of 20.7 ± 5.0 ,ug/ml, and the overall mean t112 for children was 2.52 ± 1.04 h (1) . Neonates receiving 10 mg/kg per dose had a mean peak acyclovir level of 13.9 ± 4.2 jig/ml, with a t112 of 3.78 ± 1.21 h (7). No serious toxicity was observed in our study, which was predictable since the higher acyclovir concentrations in plasma after intravenous administration were tolerated well.
The antiviral activity of acyclovir has been determined by in vitro assays, but extrapolation to in vivo inhibitory effect must be made with caution. A number of factors may alter the in vitro effects of the drug upon viral replication, and the correlation of specific drug concentrations in plasma with the clinical outcome has not been proved. Acyclovir concentrations of 0.01 to 0.7 ug/lml inhibit HSV type 1 cytopathic effects by 50%, and concentrations of 0.01 to 3.2 jig/ml inhibit HSV type 2. The in vitro inhibition of VZV occurs at 0.3 to 10.8 pLg/ml (18) . Thus, the drug concentrations required to inhibit many VZV isolates may be greater than the Cmax of 0.99 pg/ml which was obtained in children given the oral suspension of acyclovir.
The present study provides the pharmacologic basis for investigating the efficacy of oral acyclovir suspension for the treatment of herpesvirus infections in pediatric patients. Placebo-controlled clinical trials will be necessary to determine whether the peak concentrations in plasma of approximately 1.0 jig/ml obtained in our patients receiving the 600-mg/M2 dose are adequate for the treatment of infections caused by VZV and some strains of HSV. Although many patients with non-life-threatening herpesvirus infections may benefit from oral suspension therapy, these pharmacokinetic data suggest that oral acyclovir therapy is not appropriate for the initial treatment of neonatal HSV infections or other severe herpesvirus infections in children.
